Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo

Antonia E. Stephen, Peter T. Masiakos, Dorry L. Segev, Joseph P. Vacanti, Patricia K. Donahoe, David T. MacLaughlin

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Techniques of tissue engineering and cell and molecular biology were used to create a biodegradable scaffold for transfected cells to produce complex proteins. Mullerian Inhibiting Substance (MIS) causes regression of Mullerian ducts in the mammalian embryo. MIS also causes regression in vitro of ovarian tumor cell lines and primary cells from ovarian carcinomas, which derive from Mullerian structures. In a strategy to circumvent the complicated purification protocols for MIS, Chinese hamster ovary cells transfected with the human MIS gene were seeded onto biodegradable polymers of polyglycolic acid fibers and secretion of MIS confirmed. The polymer-cell graft was implanted into the right ovarian pedicle of severe combined immunodeficient mice. Serum MIS in the mice rose to supraphysiologic levels over time. One week after implantation of the polymer-cell graft, IGROV-1 human tumors were implanted under the renal capsule of the left kidney. Growth of the IGROV-1 tumors was significantly inhibited in the animals with a polymer-cell graft of MIS-producing cells, compared with controls. This novel MIS delivery system could have broader applications for other inhibitory agents not amenable to efficient purification and provides in vivo evidence for a role of MIS in the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)3214-3219
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number6
StatePublished - Mar 13 2001
Externally publishedYes


  • Mullerian Inhibiting Substance
  • Tissue engineering

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo'. Together they form a unique fingerprint.

Cite this